secwatch / observer
8-K filed October 9, 2024, 7:59 PM ET ticker BTAI CIK 0001720893
leadership confidence high sentiment negative materiality 0.60

BioXcel CCO Matthew Wiley departs; severance includes 9-mo salary, consulting through 2024

BioXcel Therapeutics, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Matthew Wiley

Senior Vice President and Chief Commercial Officer
BTAI · BioXcel Therapeutics, Inc.
Effective
2024-10-02
Filed
October 9, 2024, 7:59 PM ET
Matthew Wiley, Senior Vice President and Chief Commercial Officer of BioXcel Therapeutics, Inc. (the “ Company ”), and the Company agreed that Mr. Wiley would cease his employment with the Company, effective October 2, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthew Wiley departed as Senior Vice President and Chief Commercial Officer at BioXcel Therapeutics, Inc..

Action
cease employment
Role
Senior Vice President and Chief Commercial Officer
Exact text from the filing
Matthew Wiley, Senior Vice President and Chief Commercial Officer of BioXcel Therapeutics, Inc. (the “ Company ”), and the Company agreed that Mr. Wiley would cease his employment with the Company, effective October 2, 2024
View on SEC.gov

BioXcel Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001104659-24-107327
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.